logo-loader
viewG1 Therapeutics Inc

G1 Therapeutics jumps after announcing breast-cancer drug trilaciclib extended lives of patients on chemotherapy

Phase 2 trial demonstrated that women with metastatic triple-negative breast cancer lived significantly longer when receiving trilaciclib and chemotherapy compared with women receiving chemotherapy alone

breast cancer
The company expects to submit marketing applications in the US and Europe in 2020 to use trilaciclib to treat small-cell lung cancer

Shares of G1 Therapeutics Inc (NASDAQ:GTHX) increased by double-digits Tuesday after announcing its breast-cancer drug trilaciclib, when combined with chemotherapy, extended patients’ lives.

The company said results from a randomized Phase 2 trial of 102 patients demonstrated that women with metastatic triple-negative breast cancer (TNBC) lived significantly longer when receiving trilaciclib and chemotherapy compared with women receiving chemotherapy alone.

G1’s stock jumped 35% to $26.59 a share on strong volume. 

READ: G1 Therapeutics shares jump on new drug application

“Triple-negative breast cancer is the most aggressive type of breast cancer, and women diagnosed with metastatic TNBC need new treatment options," said CEO Mark Velleca. "We look forward to sharing these data with regulators, as well as presenting findings from this trial at a medical meeting later this year.” 

G1 is a clinical-stage biopharmaceutical company based in Research Triangle Park, North Carolina.

The company expects to submit marketing applications in the US and Europe in 2020 to use trilaciclib to treat small-cell lung cancer.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: G1 Therapeutics Inc

Price: 22.3 USD

NASDAQ:GTHX
Market: NASDAQ
Market Cap: $838.82 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

NQ Minerals' David Lenigas focused on restructuring debt and upping profits...

NQ Minerals PLC's (LON:NQMI) David Lenigas speaks to Proactive London's Andrew Scott soon after taking over as chairman at the Australia-focused mining group. Production and exploration plans aside, Lenigas also says they're in advanced talks to replace on more favourable terms all the debt...

2 hours, 45 minutes ago

2 min read